The American Pharmacist Pfizer announced this Tuesday that his Paxlovid pill, who aspires to become the first oral treatment in USA for patients with covid-19, reduces in 89% of cases the risk of hospitalization or death in adults.
In a statement, the pharmaceutical company – which is also the creator of one of the most widely used vaccines – indicated that, in addition, its most recent data confirm that the drug is a “powerful inhibitor” against the omicron variant of the coronavirus.
Paxlovid pills still have not been approved by the Food and Drug Administration (FDA) from the US, but Pfizer CEO Albert Bourla was hopeful in early December that the go-ahead can be received before the end of the month.
In clinical studies carried out by the pharmaceutical company, the reduction in the risk of hospitalization or death from COVID-19 was 89% when the pill was administered within three days of the appearance of the first symptoms; and practically the same (88%) when it was administered in the five days after the appearance of symptoms.
The study was carried out among 2,246 adults residing in North and South America, Europe, Africa and Asia (41% of them in the US) who had been diagnosed with COVID-19 in the previous five days, and all of them had at least one characteristic or medical condition that made them patients at risk of developing a disease serious.
Of all the patients given Paxlovid, only 0.7% were hospitalized within 28 days of participating in the study, and none of them died.
In contrast, among those patients who participated in the study but were not given Paxlovid (the control group), 6.5% were hospitalized or died, Pfizer reported.